According to a survey conducted in 2024, 35 percent of surveyed biopharma executives stated that the usage of the functional service provider (FSP) outsourcing model has increased compared to two years ago. This statistic describes the change in full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2022-2024.
Change in usage of full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2022-2024
Characteristic
Increased use
Decreased use
Full-service
29%
-17%
Functional service provider (FSP)
35%
-11%
-20%-10%0%10%20%30%40%50%
Add this content to your personal favorites. These can be accessed from the favorites menu in the main navigation.
You have no right to use this feature.
Make sure to contact us if you are interested in scientific citation.
You can upgrade your account to enable this functionality for all statistics.
This feature is not available with your current account.Request access
Respondents from large companies: n=64, from small/mid: n=86
Method of interview
Panel survey
Supplementary notes
The respondents are working for pharma, biopharma, or
biotech companies; they have drug development decision-making responsibility and
are director-level or above; they work in a role related to drug development; their companies have at least one compound in development; they are from the US/Canada, Europe, and Asia.
Original question: "Over the past two years, how has your company changed its full-service clinical trial outsourcing behavior?"
"Over the past two years, how has your company changed its functional service provider (FSP) outsourcing behavior?"
Learn more about how Statista can support your business.
Thermo Fisher (PPD). (September 16, 2024). Change in usage of full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2022-2024 [Graph]. In Statista. Retrieved March 13, 2025, from https://www.statista.com/statistics/1414582/biopharmaceutical-outsourcing-models-change/
Thermo Fisher (PPD). "Change in usage of full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2022-2024." Chart. September 16, 2024. Statista. Accessed March 13, 2025. https://www.statista.com/statistics/1414582/biopharmaceutical-outsourcing-models-change/
Thermo Fisher (PPD). (2024). Change in usage of full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2022-2024. Statista. Statista Inc.. Accessed: March 13, 2025. https://www.statista.com/statistics/1414582/biopharmaceutical-outsourcing-models-change/
Thermo Fisher (PPD). "Change in Usage of Full-service and Fsp Outsourcing Models among Biopharmaceutical Companies Worldwide in 2022-2024." Statista, Statista Inc., 16 Sep 2024, https://www.statista.com/statistics/1414582/biopharmaceutical-outsourcing-models-change/
Thermo Fisher (PPD), Change in usage of full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2022-2024 Statista, https://www.statista.com/statistics/1414582/biopharmaceutical-outsourcing-models-change/ (last visited March 13, 2025)
Change in usage of full-service and FSP outsourcing models among biopharmaceutical companies worldwide in 2022-2024 [Graph], Thermo Fisher (PPD), September 16, 2024. [Online]. Available: https://www.statista.com/statistics/1414582/biopharmaceutical-outsourcing-models-change/
Profit from additional features with an Employee Account
Please create an employee account to be able to mark statistics as favorites.
Then you can access your favorite statistics via the star in the header.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
